ID28545A - Turunan triazina tersubstitusi di-2,4 - Google Patents

Turunan triazina tersubstitusi di-2,4

Info

Publication number
ID28545A
ID28545A IDW00200101017A ID20011017A ID28545A ID 28545 A ID28545 A ID 28545A ID W00200101017 A IDW00200101017 A ID W00200101017A ID 20011017 A ID20011017 A ID 20011017A ID 28545 A ID28545 A ID 28545A
Authority
ID
Indonesia
Prior art keywords
triazina
substitutional
derivates
triazina derivates
substitutional triazina
Prior art date
Application number
IDW00200101017A
Other languages
English (en)
Inventor
Bart De Corte
Jan Heeres
Robert W Kavash
Michael Joseph Kukla
Koen Jeanne Alfons Van Aken
Marc Rene De Jonge
Paul Adriaan Jan Janssen
Lucien Maria Henricus Koymans
Donald William Ludovici
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ID28545A publication Critical patent/ID28545A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW00200101017A 1998-11-10 1999-11-04 Turunan triazina tersubstitusi di-2,4 ID28545A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10779998P 1998-11-10 1998-11-10
EP99203128 1999-09-24

Publications (1)

Publication Number Publication Date
ID28545A true ID28545A (id) 2001-05-31

Family

ID=26153374

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101017A ID28545A (id) 1998-11-10 1999-11-04 Turunan triazina tersubstitusi di-2,4

Country Status (34)

Country Link
US (2) US6638932B1 (id)
EP (1) EP1129079B1 (id)
JP (1) JP2002529457A (id)
KR (1) KR100620402B1 (id)
CN (1) CN1207290C (id)
AP (1) AP1636A (id)
AR (1) AR021137A1 (id)
AT (1) ATE315031T1 (id)
AU (1) AU764472B2 (id)
BG (1) BG65160B1 (id)
BR (1) BR9915176A (id)
CA (1) CA2351203C (id)
CY (1) CY1105596T1 (id)
CZ (1) CZ20011532A3 (id)
DE (1) DE69929354T2 (id)
DK (1) DK1129079T3 (id)
EA (1) EA004501B1 (id)
EE (1) EE200100253A (id)
ES (1) ES2257081T3 (id)
HR (1) HRP20010310A2 (id)
HU (1) HUP0104395A3 (id)
ID (1) ID28545A (id)
IL (2) IL143024A0 (id)
MY (1) MY126781A (id)
NO (1) NO319788B1 (id)
NZ (1) NZ510919A (id)
OA (1) OA11675A (id)
PL (1) PL196523B1 (id)
PT (1) PT1129079E (id)
SI (1) SI1129079T1 (id)
SK (1) SK6022001A3 (id)
TR (1) TR200101319T2 (id)
TW (1) TW541305B (id)
WO (1) WO2000027828A2 (id)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1636A (en) * 1998-11-10 2006-07-17 Janssen Pharmaceutica Nv 2.4-disubstituted triazine derivatives.
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US7276510B2 (en) 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
CN102503903A (zh) * 2003-02-07 2012-06-20 詹森药业有限公司 抑制hiv的1,2,4-三嗪
RU2401833C2 (ru) 2004-08-10 2010-10-20 Янссен Фармацевтика Н.В. Производные 1, 2, 4-триазин-6-она, ингибирующие вич
GB201204756D0 (en) * 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4927592B1 (id) * 1970-05-13 1974-07-18
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US4650867A (en) * 1985-03-26 1987-03-17 Ciba-Geigy Corporation Process for the preparation of 2,4,6-tris(aminophenylamino)triazines
JPH02308248A (ja) * 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
CA2174080A1 (en) 1993-10-12 1995-04-20 Paul Edward Aldrich 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
JP2002503662A (ja) * 1998-02-17 2002-02-05 テュラリク インコーポレイテッド 抗ウイルス性ピリミジン誘導体
AP1636A (en) * 1998-11-10 2006-07-17 Janssen Pharmaceutica Nv 2.4-disubstituted triazine derivatives.

Also Published As

Publication number Publication date
EE200100253A (et) 2002-12-16
DK1129079T3 (da) 2006-05-15
EA004501B1 (ru) 2004-04-29
AP1636A (en) 2006-07-17
ATE315031T1 (de) 2006-02-15
CN1325387A (zh) 2001-12-05
MY126781A (en) 2006-10-31
ES2257081T3 (es) 2006-07-16
WO2000027828A3 (en) 2000-09-21
NO20011934D0 (no) 2001-04-19
CA2351203C (en) 2009-03-24
KR100620402B1 (ko) 2006-09-13
TR200101319T2 (tr) 2001-10-22
HUP0104395A3 (en) 2003-02-28
CY1105596T1 (el) 2010-07-28
US7015221B2 (en) 2006-03-21
BR9915176A (pt) 2001-08-14
TW541305B (en) 2003-07-11
EP1129079B1 (en) 2006-01-04
AR021137A1 (es) 2002-06-12
US20050277641A1 (en) 2005-12-15
NZ510919A (en) 2003-11-28
US6638932B1 (en) 2003-10-28
AU1046200A (en) 2000-05-29
SI1129079T1 (sl) 2006-06-30
PL196523B1 (pl) 2008-01-31
NO319788B1 (no) 2005-09-12
NO20011934L (no) 2001-04-19
HK1038232A1 (en) 2002-03-08
OA11675A (en) 2005-01-12
DE69929354T2 (de) 2006-09-14
CA2351203A1 (en) 2000-05-18
CZ20011532A3 (cs) 2001-10-17
HUP0104395A2 (hu) 2002-04-29
EA200100534A1 (ru) 2001-10-22
BG65160B1 (bg) 2007-04-30
IL143024A (en) 2006-06-11
HRP20010310A2 (en) 2002-06-30
PT1129079E (pt) 2006-05-31
JP2002529457A (ja) 2002-09-10
SK6022001A3 (en) 2002-01-07
EP1129079A2 (en) 2001-09-05
CN1207290C (zh) 2005-06-22
WO2000027828A2 (en) 2000-05-18
KR20010075234A (ko) 2001-08-09
DE69929354D1 (de) 2006-03-30
BG105419A (en) 2001-11-30
PL348145A1 (en) 2002-05-06
IL143024A0 (en) 2002-04-21
AU764472B2 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
ID29241A (id) Turunan-turunan kinolin teranelasi-1,2
CU23049A3 (es) Dihidropirimidinas.
ID28723A (id) Turunan-turunan fenil yantin
ID27168A (id) Derivat-derivat diasilhidrazin
ID27846A (id) Derivat-derivat bifenil
ID26909A (id) Turunan-turunan 1,3,4-oksadiazolon
ID27703A (id) Katup putar
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
DK1149106T3 (da) 4,5-azolo-oxindoler
ID29273A (id) Derivat-derivat kroman
DE59908383D1 (de) Wegeventil
DE59904930D1 (de) Ventileinrichtung
ID27152A (id) Derivat-derivat bifenil
DE59808058D1 (de) Wegeventil
DE69926606D1 (de) Plazentaprotein 13
DE59901213D1 (de) Federüberwachungsgerät
IT245859Y1 (it) Compressore.
DE59810217D1 (de) Wegeventil
ID26368A (id) Turunan-turunan 2 deoksi higromisin
DE59907734D1 (de) Emulgatoren
DE69905102D1 (de) Spritzgiessmaschinensteuerung
DE69904825D1 (de) Bewegungsbegrenzungseinrichtung
NO993328D0 (no) Stillventil
EP1095060A4 (en) GALEKTIN 11
DE59902090D1 (de) Wegeventil